GHRP-2

GHRP-2 10MG

Manufacturer: Novo
Package: 10 mg/vial
Common Names: GHRP-2, Growth Hormone-Releasing Peptide-2, Pralmorelin

Info: GHRP-2 (Growth Hormone-Releasing Peptide-2) is a synthetic growth hormone-releasing peptide that has been investigated for its ability to stimulate endogenous growth hormone secretion. It primarily acts through the ghrelin receptor and has been studied in experimental and clinical research involving growth hormone regulation, endocrine signaling, and pituitary function.

Growth Hormone Research: GHRP-2 has been investigated for its ability to stimulate the release of growth hormone from the pituitary gland. Research has demonstrated that its effects can be influenced by dose, administration route, baseline endocrine status, and other physiological factors.

Endocrine Research: Increased growth hormone secretion may influence downstream pathways involving IGF-1, protein metabolism, glucose regulation, tissue growth, and other physiological processes. These effects have made GHRP-2 a subject of research concerning the regulation of the growth hormone axis.

Dosage Range and Duration of Use

In research and clinical protocols, subcutaneous administration typically ranges from 100 mcg to 300 mcg per dose, taken two to three times daily (often morning, post-workout, and before bed). Standard experimental cycles generally last between 8 to 12 weeks, followed by a washout period to assess pituitary response. GHRP-2 should be used only under appropriate medical supervision and according to applicable regulatory requirements.    

Side Effects

Because GHRP-2 has not been established as an approved therapeutic treatment for routine clinical use, its complete long-term safety profile has not been determined. Reported or potential reactions may include headache, dizziness, fatigue, nausea, changes in appetite, injection-site reactions, and alterations in glucose metabolism. Effects may vary depending on exposure, administration route, individual characteristics, and concurrent substances.

Post-Cycle Therapy

GHRP-2 is a growth hormone secretagogue rather than an anabolic steroid or androgenic compound. It does not require conventional post-cycle therapy (PCT) protocols associated with anabolic steroid use. However, because GHRP-2 directly influences growth hormone secretion and endocrine signaling, its use and discontinuation should be considered within an appropriate medical or research framework.

Storage:

Store lyophilized GHRP-2 according to the manufacturer's storage specifications and protect the vial from excessive heat, moisture, and direct exposure to light. After reconstitution, storage requirements and stability may depend on the diluent, concentration, preparation method, and manufacturer's instructions.